Preclinical study of a combinatorial RNAi/vaccination therapy as a potential cure for chronic hepatitis B
Thomas Michler(Helmholtz Zentrum München), Ulrike Protzer(German Center for Infection Research), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Till Bunse(Helmholtz Zentrum München), Mathias Heikenwälder(University of Tübingen), Stuart Milstein(Alnylam Pharmaceuticals (United States)), Daniela Grimm(Universitätsmedizin Göttingen), Anna D. Kosinska(Helmholtz Zentrum München)
Cited by 3
Related Papers
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
|Nature|2011|1.6k
The maternal microbiota drives early postnatal innate immune development
|Science|2016|1.2k
Therapeutic siRNA silencing in inflammatory monocytes in mice
|Nature Biotechnology|2011|837